Your Messages Inbox
Most Viewed Abstracts
1. Report Shows Shift in Starting Salaries for Physicians 2. Recommendations on the use of 18F-FDG PET in oncology 3. Taxane-based combinations as adjuvant chemotherapy of early breast cancer: a meta-analysis of randomized trials 4. Gene expression signatures, clinicopathological features, and individualized therapy in breast cancer 5. Sentinel node biopsy is important in mastectomy for ductal carcinoma in situ
Top Ten Searches
brca1 prostate-specific antigen sclc fobt egd bmi dysplasia hematologic ovarian hccYour Article Summary
See Latest ArticlesPreoperative imatinib mesylate for unresectable or locally advanced primary gastrointestinal stromal tumors
European Journal of Surgical Oncology, 06/08/09
Fiore M et al. - In unresectable or locally advanced gastrointestinal stromal tumor (GISTs), preoperative imatinib mesylate (IM) is a useful tool both to improve resectability and reduce surgical morbidity.
Methods- Aim was to investigate the effect of preoperative IM in pts with unresectable or locally advanced primary GIST
- From Jan 2003 to Jan 2008, all pts affected by bulky localized GIST were considered for preoperative IM with cytoreductive intent
- Clinical, pathological and molecular characteristics were assessed and the rate of response recorded
- Progression-free survival (PFS) was calculated according to Kaplan–Meier analysis
- 15 pts: 1 esophageal, 7 gastric, 3 duodenal, 4 rectal GISTs received preoperative IM for a median of 9 mo
- All pts had tumor shrinkage, with a median size reduction of 34%
- 1 patient had radiological CR
- In all cases an improvement of the originally planned surgical procedure was obtained:
- 3 pts initially considered unresectable underwent complete surgery
- 7 pts with initial indication for extensive surgery were more conservatively operated on
- 4 pts initially deemed at high perioperative risk underwent safe surgery
- PFS at 3 yrs from IM onset was 77%
Related Articles
Improved early event-free survival with imatinib in philadelphia chromosome-positive acute lymphoblastic leukemia: a childrens oncology group study
Journal of Clinical Oncology, 10/09/09
Relevance Score: 95%
Healthcare resource utilization and costs associated with non-adherence to imatinib treatment in chronic myeloid leukemia patients
Current Medical Research and Opinion, 11/17/09
Relevance Score: 91%
Rare incidence of congestive heart failure in gastrointestinal stromal tumor and other sarcoma patients receiving imatinib mesylate
Cancer, 11/06/09
Relevance Score: 88%
Concurrent intensive chemotherapy and imatinib before and after stem cell transplantation in newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia. Final results of the CSTIBES02 trial
Haematologica, 10/07/09
Relevance Score: 87%
Phase II Study of Neoadjuvant Imatinib in Glioblastoma: Evaluation of Clinical and Molecular Effects of the Treatment
Clinical Cancer Research, 10/01/09
Relevance Score: 87%
Today in GI Oncology...keeping you current
Receive free subspecialty "5-minute updates" via email
A prospective phase II study of cetuximab in combination with XELOX (capecitabine and oxaliplatin) in patients with metastatic and/or recurrent advanced gastric cancer
Investigational New Drugs, 12/18/09
Anemia response and safety to epoetin-beta treatment in patients with neoadjuvant therapy prior to primary digestive tract tumor surgery
Cancer Chemotherapy and Pharmacology, 12/17/09
Decreased expression of KLF6 and its significance in gastric carcinoma
Medical Oncology, 12/17/09
Sponsor
Article Search
Sponsor
Sponsor